Enteric-coated mycophenolate sodium in the treatment of refractory pemphigus

International Journal of Dermatology

Volumn 49, Issue 6, 2010, Pages 693-699

  Bongiorno, Maria Rita ^a   Pistone, Giuseppe ^a   Doukaki, Spyridoula ^a   Aricò, Mario ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOGLEIN 1 ANTIBODY; MYCOPHENOLIC ACID; PREDNISONE; ENTERIC COATED TABLET; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; ENTERIC COATED TABLET; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; REMISSION; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; DRUG COMBINATION; FOLLOW UP; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PEMPHIGUS;

ADMINISTRATION, ORAL; ADULT; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PEMPHIGUS; PREDNISONE; TABLETS, ENTERIC-COATED; TREATMENT OUTCOME;

EID: 77954203483     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2009.04291.x     Document Type: Article

References (34)

1. Ahmed AR, Graham J, Jordon R. Pemphigus: current concepts. Ann Int Med 1980, 92:396-405.
2. Simon DG, Krutchkoff D, Kaslow RA. Pemphigus in Hartford County, Connecticut, from 1972 to 1977. Arch Dermatol 1980, 116:1035-1037.
3. Goebeler M, Sitaru C, Zillikens D. Bullous autoimmune disorders: therapy. J Dtsch Dermatol Ges 2004, 2:774-793.
4. Meier-Kriesche HU, Ojo AO, Leichtman AB. Effect of mycophenolate mofetil on long-term outcomes in African-American renal transplant recipients. J Am Soc Nephrol 2000, 11:2366-2370.
5. Ojo AO, Meier-Kriesche HU, Hanson JA. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000, 69:2405-2409.
6. Enk AH, Knop J. Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet 1997, 350:494.
7. Salvadori M, Holzer H, de Mattos A. Enteric coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004, 4:231-236.
8. Schmouder R, Arns W, Merkel F. Pharmacokinetics of ERL080: a new enteric coated formulation of mycophenolic acid sodium. Transplantation 1999, 67:S203.
9. Salvadori M. Long-term administration of enteric-coated mycophenolate sodium in kidney transplant patients. Trans Proc 2005, 37:909-911.
10. Budde K, Curtis J, Knoll G. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004, 4:237-243.
11. Budde K, Knoll J, Curtis J. Safety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension study. Trans Proc 2005, 37:912-915.
12. Kobashigawa JC, Renland DG, Gerosa G. Similar efficacy and safety of enteric coated mycophenolate sodium (EC-MPS, myfortic®) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single blind, randomized, parallel group, multicenter study. J Heart Lung Transplant 2006, 25:935-941.
13. Harman KE, Gratian MJ, Bhogal BS. A study of desmoglein 1 autoantibodies in pemphigus vulgaris: racial differences in frequency and the association with a more severe phenotype. Br J Dermatol 2000, 143:343-348.
14. Rosenberg F, Sanders F, Nelson C. Pemphigus: a 20-year review of 107 patients treated with corticosteroids. Arch Dermatol 1976, 112:962-970.
15. Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 2000, 42:422-427.
16. Kanwar J, Dhar S. Factors responsible for death in patients with pemphigus. J Dermatol 1994, 21:655-659.
17. Ahmed A, Moy R. Death in pemphigus. J Am Acad Dermatol 1982, 7:221-228.
18. Bystryn J. Adjuvant therapy for pemphigus. Arch Dermatol 1984, 120:941-951.
19. Bystryn J, Steinman N. The adjuvant therapy of pemphigus: an update. Arch Dermatol 1996, 132:203-212.
20. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in cadaveric renal allograft recipients. Transplantation 1995, 60:225-232.
21. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996, 61:1029-1037.
22. Lipsky JJ. Mycophenolate mofetil. Lancet 1996, 348:1357-1359.
23. Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996, 10:77-84.
24. Sollinger HW. Mycophenolate mofetil. Kidney Int 1995, 48(Suppl.):S14-S17.
25. Hauser IA, Renders L, Radeke HH. Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 1999, 14:58-63.
26. Carter SB, Franklin TJ, Jones DF. Mycophenolic acid: an anti-cancer compound with unusual properties. Nature 1969, 223:848-850.
27. Gabardi S, Tran JL, Clarkson MR. Enteric-coated mycophenolate sodium. Ann Pharmacother 2003, 37:1685-1693.
28. Marzano AV, Dassoni F, Caputo R. Treatment of refractory blistering autoimmune diseases with mycophenolic acid. J Dermatolog Treat 2006, 17:370-376.
29. Chan L, Mulgaonkar S, Walker R. Patient -reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006, 81:1290-1297.
30. Tomlanovich S, Bolin P, Tanriover B. A three-month prospective, open-label, two cohort study to investigate the efficacy, safety and tolerability of EC-MPS in combination with cyclosporine or tacrolimus in renal transplant recipients with GI intolerance. Am J Transpl 2006, 6(Suppl. 2):487.
31. Böhm M, Beissert S, Schwarz T. Bullous pemphigoid treated with mycophenolate mofetil. Lancet 1997, 349:541.
32. Nousari HC, Griffin WA, Anhalt GJ. Successful therapy for bullous pemphigoid with mycophenolate mofetil. J Am Acad Dermatol 1998, 39:497-498.
33. Katz KH, Marks JG, Helm KF. Pemphigus foliaceus successfully treated with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol 2000, 42:514-515.
34. Enk AH, Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol 1999, 135:54-56.